Media center

Owkin partners with Hôpital Foch to validate its tumor biomarkers on human biological samples

Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x

Owkin Appoints Graeme Bell as Chief Financial Officer

Owkin launches ATLANTIS: An extensive multimodal patient data discovery program across 7 countries in 11 therapeutic areas

EY features Owkin's CEO Thomas Clozel in the "Grow Fast, Now What?" podcast (FR)

Wall Street Journal features CEO Thomas Clozel

Les Echos covers Owkin’s role in AI in healthcare for the AI Action Summit

Owkin’s CEO, Thomas Clozel named in Le Figaro’s top 7 french leaders in AI

France 24 covers Owkin’s Glioblastoma AI Hackathon

STAT interviews Owkin SVP Andrew Pierce about OKN4395

Owkin announces first patient dosed in Phase 1 Clinical Trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for patients with solid tumors

Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare Conference